Cover Image
市場調查報告書

癡呆症:開發平台分析

Dementia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245960
出版日期 內容資訊 英文 233 Pages
訂單完成後即時交付
價格
Back to Top
癡呆症:開發平台分析 Dementia - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 233 Pages
簡介

所謂癡呆症是指思考力·記憶力·推理力等日常生活機能相關的重要精神機能受損狀態。主要的症狀有記憶力衰退和妄想、興奮、人格變化、調整·運動能力、障礙等。致病的危險因子有年齡和抽煙、肥胖症、高血壓、發炎、心血管疾病等。

本報告提供全球各國治療癡呆症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

癡呆症概要

治療藥的開發

  • 癡呆症開發中產品:概要
  • 癡呆症開發中產品:比較分析

各企業開發中的癡呆症治療藥

大學/研究機關研究中的癡呆症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

癡呆症治療藥:開發中的產品的一覽(各企業)

癡呆症治療藥:研究中的產品的一覽(大學/研究機關別)

癡呆症開發治療藥的企業

  • Adamas Pharmaceuticals, Inc.
  • AgeneBio Inc.
  • Alector LLC
  • AlzProtect SAS
  • Amarantus Bioscience Holdings, Inc.
  • Axon Neuroscience SE
  • Axovant Sciences Ltd.
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Biotie Therapies Corp.
  • Boehringer Ingelheim GmbH
  • Chase Pharmaceuticals Corporation
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Heptares Therapeutics Limited
  • Hyundai Pharmaceutical Co., Ltd.
  • Ildong Pharmaceutical Co., Ltd.
  • Immungenetics AG
  • ImStar Therapeutics Inc.
  • Integrative Research Laboratories Sweden AB
  • Intellect Neurosciences, Inc.
  • Intra-Cellular Therapies, Inc.
  • MediPost Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Neurimmune Holding AG
  • Neurodyn Inc.
  • Oryzon Genomics S.A.
  • Ovid Therapeutics Inc.
  • P2D Bioscience
  • Pacific Northwest Biotechnology, LLC
  • Pivot Pharmaceuticals Inc
  • Sinil Pharmaceutical Co., Ltd
  • Stelic Institute & Co., Inc.
  • 大日本住友製藥
  • Sylentis S.A.U.
  • TauRx Therapeutics Ltd.
  • WhanIn Pharmaceutical Co., Ltd.

癡呆症:治療藥的評估

  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AADvac-1
  • Antisense Oligonucleotides to Inhibit microRNA for Neurology
  • Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia
  • AVCRI-104P3
  • AZP-2006
  • BAN-0805
  • BI-409306
  • CB-2233
  • CB-8411
  • choline alfoscerate SR
  • CPC-201
  • CPC-252
  • D-217
  • dehydroevodiamine hydrochloride
  • Drugs for Dementia
  • Drugs to Agonize c-MET for Dementia
  • Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment
  • DWJ-1365
  • E-2609
  • eltoprazine
  • encenicline hydrochloride
  • FRM-0334
  • GIBH-130
  • Gln-1062
  • GTC-6000
  • gugulipid
  • HOB-075
  • HTL-18318
  • IRL-752
  • ITI-007
  • KR-12
  • levetiracetam
  • LH-026
  • LUAF-20513
  • MM-201
  • Monoclonal Antibodies for Dementia and Alzheimer's Disease
  • Monoclonal Antibodies to Inhibit Tau for CNS Disorders
  • NAT
  • nelotanserin
  • Neurostem
  • NI-205
  • NI-308
  • NNC-269100
  • NP-001
  • OG-635
  • ORY-2001
  • OV-201
  • P-003
  • PD-2015
  • PD-2016
  • PD-2024
  • PD-2244
  • PD-61W3
  • Peptide to Inhibit BACE for Cerebropathy and Dementia
  • PST-900
  • RVT-101
  • salicylamine
  • SIN-1502
  • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders
  • Small Molecule to Activate LPL for CNS and Metabolic Disorders
  • Small Molecule to Inhibit Glycogene 5 for Dementia
  • Small Molecules for Frontotemporal Dementia
  • Small Molecules for Ophthalmology and CNS Disorders
  • Small Molecules to Agonize HGFR for CNS Disorders
  • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia
  • Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease
  • SND-14
  • SYN-120
  • Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders
  • TAK-070
  • TauC-3
  • TPI-287
  • TRx-0237
  • TTT-3002
  • WIB-1001C
  • zonisamide

癡呆症治療藥:開發中產品的最新趨勢

癡呆症治療藥:開發暫停的產品

癡呆症治療藥:開發中止的產品

癡呆症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8345IDB

Summary

Global Markets Direct's, 'Dementia - Pipeline Review, H2 2016', provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dementia
  • The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects
  • The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dementia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dementia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dementia Overview
  • Therapeutics Development
    • Pipeline Products for Dementia - Overview
    • Pipeline Products for Dementia - Comparative Analysis
  • Dementia - Therapeutics under Development by Companies
  • Dementia - Therapeutics under Investigation by Universities/Institutes
  • Dementia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dementia - Products under Development by Companies
  • Dementia - Products under Investigation by Universities/Institutes
  • Dementia - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • AgeneBio Inc.
    • Alector LLC
    • AlzProtect SAS
    • Amarantus Bioscience Holdings, Inc.
    • Anavex Life Sciences Corp.
    • Axon Neuroscience SE
    • Axovant Sciences Ltd.
    • BioArctic Neuroscience AB
    • Biogen Inc
    • Biotie Therapies Corp.
    • Boehringer Ingelheim GmbH
    • Chase Pharmaceuticals Corporation
    • Cortice Biosciences, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • FORUM Pharmaceuticals Inc.
    • H. Lundbeck A/S
    • Heptares Therapeutics Limited
    • Hyundai Pharmaceutical Co., Ltd.
    • Ildong Pharmaceutical Co., Ltd.
    • Immungenetics AG
    • ImStar Therapeutics Inc.
    • Integrative Research Laboratories Sweden AB
    • Intellect Neurosciences, Inc.
    • Intra-Cellular Therapies, Inc.
    • INVENT Pharmaceuticals, Inc.
    • M3 Biotechnology, Inc.
    • MediPost Co., Ltd.
    • Neuraltus Pharmaceuticals, Inc.
    • Neurimmune Holding AG
    • Neurodyn Inc.
    • Oryzon Genomics SA
    • Otsuka Holdings Co., Ltd.
    • P2D Bioscience
    • Pacific Northwest Biotechnology, LLC
    • Pivot Pharmaceuticals Inc
    • Sinil Pharmaceutical Co., Ltd
    • Stelic Institute & Co., Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Sylentis S.A.U.
    • Takeda Pharmaceutical Company Limited
    • TauRx Therapeutics Ltd.
    • Voyager Therapeutics, Inc.
    • WhanIn Pharmaceutical Co., Ltd.
    • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Dementia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile
    • (donepezil hydrochloride + solifenacin succinate) - Drug Profile
    • AADvac-1 - Drug Profile
    • AD-35 - Drug Profile
    • ANAVEX-371 - Drug Profile
    • Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile
    • ASN-561 - Drug Profile
    • AVP-786 - Drug Profile
    • AZP-2006 - Drug Profile
    • BAN-0805 - Drug Profile
    • BI-409306 - Drug Profile
    • CB-2233 - Drug Profile
    • CB-8411 - Drug Profile
    • choline alfoscerate SR - Drug Profile
    • D-217 - Drug Profile
    • dehydroevodiamine hydrochloride - Drug Profile
    • Drugs for Dementia - Drug Profile
    • Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile
    • Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
    • DWJ-1365 - Drug Profile
    • E-2609 - Drug Profile
    • eltoprazine - Drug Profile
    • encenicline hydrochloride - Drug Profile
    • FRM-0334 - Drug Profile
    • GIBH-130 - Drug Profile
    • Gln-1062 - Drug Profile
    • GTC-6000 - Drug Profile
    • gugulipid - Drug Profile
    • HOB-075 - Drug Profile
    • HTL-18318 - Drug Profile
    • intepirdine - Drug Profile
    • INV-331 - Drug Profile
    • IRL-752 - Drug Profile
    • ITI-007 - Drug Profile
    • levetiracetam - Drug Profile
    • LUAF-20513 - Drug Profile
    • MM-201 - Drug Profile
    • Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia - Drug Profile
    • Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile
    • Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile
    • monosodium luminol - Drug Profile
    • NAT - Drug Profile
    • nelotanserin - Drug Profile
    • Neurostem - Drug Profile
    • NI-205 - Drug Profile
    • NI-308 - Drug Profile
    • NNC-269100 - Drug Profile
    • NP-001 - Drug Profile
    • ORY-2001 - Drug Profile
    • P-003 - Drug Profile
    • PD-2015 - Drug Profile
    • PD-2016 - Drug Profile
    • PD-2024 - Drug Profile
    • PD-2244 - Drug Profile
    • Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile
    • PST-900 - Drug Profile
    • salicylamine - Drug Profile
    • SIN-1502 - Drug Profile
    • Small Molecule for Dementia - Drug Profile
    • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile
    • Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile
    • Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile
    • Small Molecules for Frontotemporal Dementia - Drug Profile
    • Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
    • Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile
    • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia - Drug Profile
    • Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile
    • SND-14 - Drug Profile
    • SYN-120 - Drug Profile
    • Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile
    • TAK-070 - Drug Profile
    • TAK-071 - Drug Profile
    • TauC-3 - Drug Profile
    • tolfenamic acid - Drug Profile
    • TPI-287 - Drug Profile
    • TRx-0237 - Drug Profile
    • TTT-3002 - Drug Profile
    • VYTAU-01 - Drug Profile
    • WIB-1001C - Drug Profile
    • zonisamide - Drug Profile
  • Dementia - Dormant Projects
  • Dementia - Discontinued Products
  • Dementia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dementia, H2 2016
  • Number of Products under Development for Dementia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Dementia - Pipeline by AgeneBio Inc., H2 2016
  • Dementia - Pipeline by Alector LLC, H2 2016
  • Dementia - Pipeline by AlzProtect SAS, H2 2016
  • Dementia - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Dementia - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Dementia - Pipeline by Axon Neuroscience SE, H2 2016
  • Dementia - Pipeline by Axovant Sciences Ltd., H2 2016
  • Dementia - Pipeline by BioArctic Neuroscience AB, H2 2016
  • Dementia - Pipeline by Biogen Inc, H2 2016
  • Dementia - Pipeline by Biotie Therapies Corp., H2 2016
  • Dementia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2016
  • Dementia - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Dementia - Pipeline by Eisai Co., Ltd., H2 2016
  • Dementia - Pipeline by Eli Lilly and Company, H2 2016
  • Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
  • Dementia - Pipeline by H. Lundbeck A/S, H2 2016
  • Dementia - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016
  • Dementia - Pipeline by Immungenetics AG, H2 2016
  • Dementia - Pipeline by ImStar Therapeutics Inc., H2 2016
  • Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
  • Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2016
  • Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Dementia - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Dementia - Pipeline by M3 Biotechnology, Inc., H2 2016
  • Dementia - Pipeline by MediPost Co., Ltd., H2 2016
  • Dementia - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2016
  • Dementia - Pipeline by Neurimmune Holding AG, H2 2016
  • Dementia - Pipeline by Neurodyn Inc., H2 2016
  • Dementia - Pipeline by Oryzon Genomics SA, H2 2016
  • Dementia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Dementia - Pipeline by P2D Bioscience, H2 2016
  • Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016
  • Dementia - Pipeline by Pivot Pharmaceuticals Inc, H2 2016
  • Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016
  • Dementia - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Dementia - Pipeline by Sylentis S.A.U., H2 2016
  • Dementia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Dementia - Pipeline by TauRx Therapeutics Ltd., H2 2016
  • Dementia - Pipeline by Voyager Therapeutics, Inc., H2 2016
  • Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2016
  • Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dementia - Dormant Projects, H2 2016
  • Dementia - Dormant Projects (Contd..1), H2 2016
  • Dementia - Dormant Projects (Contd..2), H2 2016
  • Dementia - Dormant Projects (Contd..3), H2 2016
  • Dementia - Dormant Projects (Contd..4), H2 2016
  • Dementia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Dementia, H2 2016
  • Number of Products under Development for Dementia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top